A review of research on the use of testosterone replacement therapy in men with a history of prostate cancer and in men with elevated prostate cancer risk found no evidence of statistically significant associations between such treatment and cancer progression.
The finding supports the conclusion of several other recent studies that have attempted to evaluate replacement therapy in such populations and failed to find evidence of danger.
Such work has begun to overturn the longstanding assumption that testosterone supplements would prove deadly to many men with elevated prostate-cancer risk, but the authors of the new review say that large, randomized trials will be needed to justify sweeping changes to treatment strategies.
*Excerpt from MD Magazine